Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Aficamten by Cytokinetics for Diastolic Heart Failure (HFpEF): Likelihood of Approval
Aficamten is under clinical development by Cytokinetics and currently in Phase I for Diastolic Heart Failure (HFpEF). According to GlobalData,...
Aficamten by Cytokinetics for Hypertrophic Cardiomyopathy: Likelihood of Approval
Aficamten is under clinical development by Cytokinetics and currently in Phase III for Hypertrophic Cardiomyopathy. According to GlobalData, Phase III...
Risk adjusted net present value: What is the current valuation of Cytokinetics's Aficamten?
Aficamten is a small molecule commercialized by Cytokinetics, with a leading Phase III program in Hypertrophic Cardiomyopathy. According to Globaldata,...